Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVERSION: FOLFOXIRI + Bevacizumab for Liver-Only mCRC
NCT03401294Phase 2Recruiting
- Sponsor
- University of Saskatchewan
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, fluorouracil, folinic acid, oxaliplatin, irinotecan in metastatic colorectal cancer (mCRC), sponsored by University of Saskatchewan. Started May 2025; status: recruiting.
02
Drugs
bevacizumabfluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03401294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401294.